公开(公告)号：WO2022140776A1

公开(公告)日：2022-06-30

申请号：PCT/US2021/073059

申请日：2021-12-21

Applicant: MULTIVIR INC.

Inventor： SOBOL, Robert, E. ,  MENANDER, Kerstin, B. ,  WIEDERHOLD, Dora ,  CHADA, Sunil

IPC: A61K48/00 ,  A61P31/00

Abstract: Provided herein are methods and compositions for suppressing or preventing an infection in a subject infected by a pathogen or decreasing organ or tumor tissue fibrosis that involve administering to the subject a composition that includes a therapeutically effective amount of a p53 therapy. Also disclosed are methods of suppressing tumor stroma by contacting the tumor stroma with the p53 therapy, wherein the p53 suppresses tumor stroma activities.

公开(公告)号：WO2017189976A1

公开(公告)日：2017-11-02

申请号：PCT/US2017/030077

申请日：2017-04-28

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  YALE UNIVERSITY

Inventor： SYMMANS, William, Fraser ,  SINN, Bruno ,  HATZIS, Christos ,  FU, Chunxiao ,  LAU, Rosanna

IPC: C12Q1/68 ,  G06F19/20 ,  G01N33/574 ,  G01N33/53 ,  A61K31/56 ,  C07K14/575 ,  C07K14/705

Abstract: Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER/PR index), and may have additional consideration for the proportion of ER gene (ESRl) RNA transcripts that contain a mutation relative to the value of the SETER/PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER/PR index.

Abstract translation: 本文提供了基于雌激素受体（ER）和孕酮受体（PR）相关基因的指数确定肿瘤对激素（内分泌）治疗的敏感性的方法，称为对内分泌的敏感性 治疗指数（SETER / PR指数），并且可以对含有相对于SETER / PR指数值的突变的ER基因（ESR1）RNA转录物的比例进行额外考虑。 进一步提供了通过SETER / PR指数治疗被确定为对内分泌治疗敏感的乳腺癌患者的方法。

公开(公告)号：WO2017044488A1

公开(公告)日：2017-03-16

申请号：PCT/US2016/050554

申请日：2016-09-07

Applicant: CELLULAR DYNAMICS INTERNATIONAL, INC.

Inventor： MEYER, Nathan ,  CHASE, Lucas ,  STANKEWICZ, Casey

IPC: C12N5/079 ,  C12N5/00

CPC classification number: C12N5/0081 ,  C12N5/0621 ,  C12N5/0696 ,  C12N2506/03 ,  C12N2510/00

Abstract: Provided herein are methods of enriching a retinal pigment epithelium (RPE) cell population derived from stem cells. Such a method may comprise removing contaminating cells through the depletion of CD24 positive cells, CD56 positive cells, and/or CD90 positive cells from a starting population of RPE cells.

Abstract translation: 本文提供了富集源自干细胞的视网膜色素上皮细胞（RPE）细胞群的方法。 这样的方法可以包括通过从起始RPE细胞群中消耗CD24阳性细胞，CD56阳性细胞和/或CD90阳性细胞来去除污染细胞。

公开(公告)号：WO2014071361A1

公开(公告)日：2014-05-08

申请号：PCT/US2013/068468

申请日：2013-11-05

Applicant: RUBICON GENOMICS

Inventor： KURIHARA, Takao ,  KAMBEROV, Emmanuel ,  TESMER, Tim ,  LANGMORE, John

IPC: C12Q1/68

CPC classification number: C12N15/1065 ,  C12Q1/6855 ,  C12Q2525/155 ,  C12Q2525/191 ,  C12Q2525/301 ,  C12Q2563/179

Abstract: Methods of barcoding nucleic acids, such as genomic DNA, are provided herein. In some embodiments, a fragment of genomic DNA may comprise a first and a second barcode.

Abstract translation: 本文提供了条形码核酸例如基因组DNA的方法。 在一些实施方案中，基因组DNA的片段可以包含第一和第二条形码。

公开(公告)号：WO2013052772A2

公开(公告)日：2013-04-11

申请号：PCT/US2012/058910

申请日：2012-10-05

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： LIU, Yong-jun ,  LU, Ning ,  BOVER, Laura ,  TSURUSHITA, Naoya ,  TSO, J., Yun ,  KUMAR, Shankar

IPC: C07K16/18 ,  A61K39/395 ,  A61P35/00 ,  A61P37/08

CPC classification number: C07K16/18 ,  C07K16/2803 ,  C07K2317/76

Abstract: Anti-human sema4A antibodies useful in treating autoimmune diseases, cancers and other disease are provided herein. Anti-human sema4A antibodies can inhibit T cell proliferation and Th2 differentiation induced by IL-4, anti-CD3, anti-CD28 and recombinant sema4A.

Abstract translation: 本文提供了可用于治疗自身免疫疾病，癌症和其他疾病的抗人sema4A抗体。 抗人sema4A抗体可以抑制IL-4，抗CD3，抗CD28和重组sema4A诱导的T细胞增殖和Th2分化。

公开(公告)号：WO2012170614A3

公开(公告)日：2012-12-13

申请号：PCT/US2012/041228

申请日：2012-06-07

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  LIN, Steven, H. ,  HEYMACH, John ,  WANG, Jing ,  MINNA, John ,  GIRARD, Luc

Inventor： LIN, Steven, H. ,  HEYMACH, John ,  WANG, Jing ,  MINNA, John ,  GIRARD, Luc

IPC: C12Q1/68 ,  G01N33/574

Abstract: Provided herein are unique sets of genes that are regulated by methylation in non-small cell lung cancer ("NSCLC") that are useful as a biomarker or in an assay for determining, diagnosing or subtyping lung cancer and/or the outcome of certain drug therapies.

公开(公告)号：WO2012148799A1

公开(公告)日：2012-11-01

申请号：PCT/US2012/034361

申请日：2012-04-20

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  ANDERSSON, Borge, S. ,  VALDEZ, Benigno, C. ,  TARRANT, Jeffrey

Inventor： ANDERSSON, Borge, S. ,  VALDEZ, Benigno, C. ,  TARRANT, Jeffrey

IPC: A61K9/107 ,  A61K47/10 ,  A61K9/00

CPC classification number: A61K31/496 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/1075 ,  A61K31/255 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26

Abstract: There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases.

Abstract translation: 可以提供具有改善的溶解度和稳定性的亲脂性药剂的组合物。 例如，可以提供包含亲脂性药剂和两亲性聚合物溶剂如PEG400但基本上不含有机溶剂和未溶解颗粒的非水性组合物。 组合物可以用所需的水性稀释剂如用于胃肠外给药的输注液进一步稀释至受试者例如人。 组合物可用于治疗对亲脂性试剂如感染性疾病，恶性或自身免疫性疾病敏感的疾病或病症。

公开(公告)号：WO2012030956A2

公开(公告)日：2012-03-08

申请号：PCT/US2011/049958

申请日：2011-08-31

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  SEN, Subrata ,  WANG, Jin

Inventor： SEN, Subrata ,  WANG, Jin

IPC: C12Q1/68 ,  C12N15/11

CPC classification number: C12Q1/6827 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: Methods for the diagnosis and/or monitoring of pancreatic cancer by detection of micro-RNAs (miRNA) are provided. In certain embodiments, detection of miR-21, miR-210, miR-155, and/or miR-196a in the plasma, blood, or pancreatic juice of a subject, such as a human patient, may be used to detect, diagnose, or monitor a pancreatic cancer.

Abstract translation: 提供了通过检测微小RNA（miRNA）来诊断和/或监测胰腺癌的方法。 在某些实施方案中，对象例如人类患者的血浆，血液或胰液中miR-21，miR-210，miR-155和/或miR-196a的检测可用于检测，诊断 或监测胰腺癌。

公开(公告)号：WO2011159797A2

公开(公告)日：2011-12-22

申请号：PCT/US2011/040519

申请日：2011-06-15

Applicant: CELLULAR DYNAMICS INTERNATIONAL, INC. ,  NUWAYSIR, Emile ,  KENDRICK-PARKER, Chris ,  SEAY, Nicholas

Inventor： NUWAYSIR, Emile ,  KENDRICK-PARKER, Chris ,  SEAY, Nicholas

IPC: C12N5/074 ,  C12N5/10 ,  C12N15/65 ,  C12N15/85 ,  C12Q1/02 ,  G01N33/15

CPC classification number: G01N33/5023 ,  G01N33/5014 ,  G01N33/5041 ,  G01N33/5073

Abstract: The invention generally features methods for providing engineered pluripotent stem cells that can be used to study biological response and pathways, including differentiation and drug effects. For example, these cells are provided comprising two or more exogenous expression cassettes including a selectable or screenable marker under the control of different condition-responsive regulatory elements, such as differentiation-responsive promoters or regulatory element of a receptor, drug target, drug metabolizing enzyme or signaling pathway gene. Also provided are sets of stem cell lines each comprising a different exogenous expression cassette including a selectable or screenable marker under the control of a different condition-responsive regulatory element.

Abstract translation: 本发明通常具有用于提供可用于研究生物反应和途径（包括分化和药物作用）的工程多能干细胞的方法。 例如，提供这些细胞包含两种或更多种外源性表达盒，其包括在不同的条件反应性调控元件的控制下的可选择或可筛选标记，例如受体的分化反应性启动子或调节元件，药物靶标，药物代谢酶 或信号通路基因。 还提供了一组干细胞系，其各自包含不同的外源表达盒，其包含在不同的条件响应性调节元件的控制下的可选择或可筛选标记。

公开(公告)号：WO2011093851A1

公开(公告)日：2011-08-04

申请号：PCT/US2010/022085

申请日：2010-01-26

Applicant: SCOTT AND WHITE MEMORIAL HOSPITAL AND SCOTT, SHERWOOD, AND BRINDLEY FOUNDATION ,  CHILDS, Ed, W. ,  SMYTHE, W. Roy

Inventor： CHILDS, Ed, W. ,  SMYTHE, W. Roy

IPC: A61K38/16 ,  A61K31/355 ,  A61K31/375 ,  A61P9/00

CPC classification number: A61K31/355 ,  A61K31/375 ,  A61K38/16

Abstract: A method comprising preparing a vascular hyperpermeability treatment composition comprising an apoptosis regulating protein, a antioxidant, a mitochondrial modulator, a biological effector molecule, or combinations thereof in a form deliverable to a mammal; whereby an effective amount of the composition raises the threshold for apoptosis and/or prevents or lessens the occurrence of vascular hyperpermeability. A method comprising preventing hyperpermeability associated with hemorrhagic shock via preparing a composition in a form deliverable to a mammal, the composition comprising an apoptosis regulating protein, a antioxidant, a mitochondrial modulator, a biological effector molecule, or combinations thereof; and raising the threshold for apoptosis in a mammal's endothelial cells by administering an effective amount of said antioxidant; whereby said raising the threshold for apoptosis prevents said hyperpermeability.

Abstract translation: 一种方法，包括以可递送给哺乳动物的形式制备包含凋亡调节蛋白，抗氧化剂，线粒体调节剂，生物效应分子或其组合的血管高渗透性治疗组合物; 由此有效量的组合物提高细胞凋亡的阈值和/或预防或减少血管高渗透性的发生。 一种包括通过制备可递送给哺乳动物的形式的组合物来预防与出血性休克相关的高渗透性的方法，所述组合物包含凋亡调节蛋白，抗氧化剂，线粒体调节剂，生物效应分子或其组合; 并通过施用有效量的所述抗氧化剂来提高哺乳动物的内皮细胞中细胞凋亡的阈值; 由此提高凋亡阈值可防止所述高渗透性。